Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: A prospective crossover study

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 12, 2014, Pages 2044-2048

  Alamelu, J ^a   Bevan, D ^a   Sorensen, B ^a,b   Rangarajan, S ^a,c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ALNYLAM PHARMACEUTICALS   (United States)

^c BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

Author keywords

Factor IX; Half life; Hemophilia B; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BLOOD CLOTTING FACTOR 9 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 9; THROMBIN; BLOOD CLOTTING FACTOR 9; RECOMBINANT PROTEIN;

ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG HALF LIFE; FOLLOW UP; HEMOPHILIA B; HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; WILCOXON SIGNED RANKS TEST; ADOLESCENT; ADULT; AGED; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; MALE; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDY; REPRODUCIBILITY; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CROSS-OVER STUDIES; FACTOR IX; HEMOPHILIA B; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; THROMBIN; TIME FACTORS; YOUNG ADULT;

EID: 84916625055     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12756     Document Type: Article

References (20)

1. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-9.
2. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL, Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
3. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: prothrombin complex concentrates - evaluation of safety and thrombogenicity. Crit Care 2011; 15: 201-9.
4. Gater A, Thomson TA, Strandberg-Larsen M. Haemophilia B: impact on patients and economic burden of disease. Thromb Haemost 2011; 106: 398-404.
5. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline. Haemophilia 2008; 14: 671-84.
6. White G, Shapiro A, Ragni M, Garzone P, Goodfellow J, Tubridy K, Courter S. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35: 33-8.
7. Ewenstein BM, Joist JH, Shapiro AD, Hofstra TC, Leissinger CA, Seremetis SV, Broder M, Mueller-Velten G, Schwartz BA, Mononine Comparison Study Group. Pharmacokinetic analysis of plasma-derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
8. Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002; 87: 431-5.
9. Björkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia 2011; 17: 179-84.
10. Dargaud Y, Beguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC, Hemker HC, Negrier C. Evaluation of thrombin generation capacity in plasma from patients with severe haemophilia A and B. Thromb Haemost 2005; 93: 475-80.
11. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116: 5734-7.
12. Young G, Sorensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 2013; 121: 1944-50.
13. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
14. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261-5.
15. Wolberg AS. Plasma and cellular contributions to fibrin network formation, structure and stability. Haemophilia 2010; 16: 7-12.
16. Kisker CT, Eisberg A, Schwartz B, the Mononine Study Group. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia 2003; 9: 279-84.
17. Lissitchkov T, Matysiak M, Zavilska K, Laguna P, Gercheva L, Antonov A, Moret A, Caunedo P, Aznar JA, Woodward MK, Paez A. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine) and a recombinant factor IX (BeneFIX) in patients with severe haemophilia B. Haemophilia 2013; 19: 674-8.
18. Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008; 14: 83-92.
19. Dargaud Y, Lienhart A, Meunier S, Hequet O, Chavanne H, Chamouard V, Marin S, Negrier C. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia 2005; 11: 552-8.
20. Yu Y, Millar CM. Measurement of factor IX activity in plasma-derived and recombinant concentrates: insights from thrombin generation and activation-based assays. J Thromb Haemost 2014; 12: 62-70.